Follow The Filings

TSHA position history

The shares of Taysha Gene Therapies (TSHA) that Palo Alto Investors LP reported in each quarter’s 13F.

Equity, COM SHS

Shares held by quarter

New Add Reduce Exit

  1. 2023 Q4: 1,059,722 shares, $1.9M, 0.17% of portfolio, New
  2. 2024 Q1: 811,268 shares, $2.3M, 0.26% of portfolio, Reduce −23.4%
  3. 2024 Q2: 811,268 shares, $1.8M, 0.21% of portfolio
  4. 2024 Q3: 811,268 shares, $1.6M, 0.21% of portfolio
  5. 2024 Q4: 811,268 shares, $1.4M, 0.22% of portfolio
  6. 2025 Q1: 1,419,468 shares, $2M, 0.38% of portfolio, Add +75.0%
  7. 2025 Q2: 1,246,033 shares, $2.9M, 0.61% of portfolio, Reduce −12.2%
  8. 2025 Q3: 1,246,033 shares, $4.1M, 0.75% of portfolio
  9. 2025 Q4: 1,183,195 shares, $6.5M, 0.91% of portfolio, Reduce −5.0%
  10. 2026 Q1: 1,391,382 shares, $6.2M, 0.95% of portfolio, Add +17.6%
  11. 2026 Q2: 1,391,382 shares, $9.5M, 1.3% of portfolio
  12. 2026 Q3: 1,337,217 shares, $6.5M, 0.97% of portfolio, Reduce −3.9%
Holdings date Value % of holdings Shares Filing date All 13F holders